Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 11/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | TAS2R8 | Q9NYW2 | 3/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6518863 | 0.92 | MAPT (0.44) | IGF1RCNR1TAS2R8RAB9A | |
| SCHEMBL1974598 | 0.83 | CNR1 (0.55) | CNR1 | |
| SCHEMBL4114430 | 0.80 | IGF1R (0.40) | IGF1RAURKATAS2R8 | |
| SCHEMBL1974199 | 0.80 | AR (0.51) | — | |
| Hydrochloric Acid SCHEMBL3528116 | 0.80 | IGF1R (0.39) | IGF1RAURKATAS2R8 | |
| SCHEMBL1976295 | 0.77 | IGF1R (0.50) | IGF1RTAS2R8 | |
| SCHEMBL1972192 | 0.76 | CNR1 (0.61) | IGF1RCNR1 | |
| SCHEMBL6524797 | 0.75 | CNR1 (0.54) | CNR1RAB9A | |
| SCHEMBL6527708 | 0.75 | AR (0.49) | — | |
| SCHEMBL8002084 | 0.74 | CNR1 (0.58) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252591-B1 | ARYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI AVENTIS (FR) | 2011-06-22 | — | — | EP | disclosed |
| US-20110053947-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | US | disclosed |
| US-20110053947-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053947-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | PGC, LIPC, CEL | IGF1R 739/4885CNR1 277/4885AURKA 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.